Enquirer Consulting Group

Reachable Buyer Map

Prepared for Peter Ganem · Bausch+Ströbel · August 2026
In this market, first contact usually happens at a trade show, through the engineering firm that designs the suite, or through a plant manager who ran the same equipment at a previous site. All three reach the sites that already know the name, and all three are quiet about the rest. This map is the rest, counted in the United States because that is where the largest concentration of sterile fill and finish capacity sits and where the line is signed locally, whoever builds it: the segments that buy filling and closing lines, who signs inside each one, and roughly how many sit there.
Sterile injectable contract manufacturers
The segment that buys capacity ahead of demand, because a filled order book is the product. Fill and finish capability is what they win work on, so a line decision here is a commercial decision as much as an engineering one.
Who signs: VP of manufacturing or technical operations, director of engineering, capital projects lead, site director, with procurement on the paper.
120 to 200
US sites offering sterile fill and finish under contract; the sterile-capable slice of a much larger contract manufacturing base
Commercial biologics and vaccine producers
Own-label manufacturers running their own filling suites. Long qualification, long memory, and a replacement cycle measured in decades, which makes the moment a line is specified the only moment that counts.
Who signs: head of technical operations, director of manufacturing science, site engineering lead, validation and quality director, and the sponsor who takes it to the capital committee.
150 to 250
US establishments producing biologics, vaccines or other injectables under their own label
Clinical-stage developers moving to commercial supply
The largest group by count and the smallest by immediate need, because most outsource filling until a program reaches approval. Worth naming precisely: the buying event is the decision to take supply in house, and it is usually visible long before a purchase order exists.
Who signs: chief technical officer, head of CMC, VP of manufacturing, and the chief executive on the first line a company ever buys.
800 to 1,200
US developers with injectable or biologic programs in clinical stages; only a minority will ever build their own suite
Registered outsourcing facilities
Compounding operations that register federally and fill on smaller formats. Small enough to work end to end, published in full by the regulator, and rarely on anyone's target list because from the outside the segment does not look like pharma.
Who signs: owner or president, director of operations, pharmacist in charge, quality lead.
Roughly 65 to 90 nationally
federally registered outsourcing facilities; unusually, the whole segment is published and countable
Animal health and veterinary injectables
The same sterile requirements, a different regulator, and far less competition for attention. Vial and cartridge formats dominate, and the group deciding is usually smaller than on the human side.
Who signs: plant manager, operations director, engineering manager, and the general manager of the business unit.
80 to 140
US establishments producing veterinary injectables and biologics
Combination product and delivery device makers
Prefilled syringes, autoinjectors and on-body delivery. They register as device makers rather than drug makers, so they sit in a separate federal register entirely and a standard pharma list misses them.
Who signs: VP of operations, director of manufacturing engineering, the program manager for a launch, quality systems lead.
250 to 450
US device establishments working in injectable drug delivery, out of roughly 12,500 to 13,500 device establishments in total

Where the openings are

1
The register names the site, not the project. Public federal registers list every drug and device establishment in the country, roughly 9,500 to 10,000 on the drug side alone. What they do not list is which of those is expanding. Pairing the register with public capacity and approval announcements is what turns a list into a queue.
2
Six segments, about 1,465 to 2,330 organizations in the United States. Large enough to be worth working systematically, small enough that a channel built on named roles can cover it inside a year. A trade show reaches whoever walks the aisle that week. The rest of that list is not unqualified, it is simply not in the room.
3
One machine, three signatures. Engineering specifies, quality approves, finance funds, and in this market those are three different people with three different reasons to say yes. A channel built on a single relationship usually reaches one of the three, and the other two hear about it late.
4
Outsourcing facilities and animal health are the segments lists under-work. Both are enumerated in full by public registers and both buy smaller formats. Anyone buying an off-the-shelf pharma list gets the household names and misses these two entirely, which is exactly why they stay open.
Built from public federal establishment registers covering United States drug and device establishments, current to mid 2026, and from the published register of outsourcing facilities. Counts are banded deliberately. They describe registered establishments rather than companies, so a firm with three registered sites appears three times, and segment splits are estimated from registration codes rather than from any private database. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com